To effectively target pSTAT3, we prepared Lip-FLLL32, a liposome-formulated pSTAT3 inhibitor FLLL32, which efficiently suppressed cell growth and colony formation in pancreatic cancer cells with constitutively activated STAT3 in vitro and inhibited xenograft tumor growth in vivo, accompanied by reduction of pSTAT3 and its target genes expression. This evidence concerns the gene STAT3 and pancreatic neoplasm.